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Abstract. We investigated mitochondrial toxicity of four 
lipophilic stains (cerivastatin, fluvastatin, atorvastatin, 
simvastatin) and one hydrophilic statin (pravastatin). In 
L6 cells (rat skeletal muscle cell line), the four lipophilic 
statins (100 µmol/l) induced death in 27–49% of the cells. 
Pravastatin was not toxic up to 1 mmol/l. Cerivastatin, 
fluvastatin and atorvastatin (100 µmol/l) decreased the 
mitochondrial membrane potential by 49–65%, whereas 
simvastatin and pravastatin were less toxic. In isolated rat 
skeletal muscle mitochondria, all statins, except pravas-
tatin, decreased glutamate-driven state 3 respiration and 
respiratory control ratio. Beta-oxidation was decreased 
by 88–96% in the presence of 100 µmol/l of the lipophilic 
statins, but only at higher concentrations by pravastatin. 
Mitochondrial swelling, cytochrome c release and DNA 
fragmentation was induced in L6 cells by the four lipo-
philic statins, but not by pravastatin. Lipophilic statins 
impair the function of skeletal muscle mitochondria, 
whereas the hydrophilic pravastatin is significantly less 
toxic.
Keywords. Rhabdomyolysis, statins, apoptosis, mitochondria, β-oxidation, respiratory chain
Introduction
Statins (3-hydroxy-3-methyl-glutaryl coenzyme A reduc-
tase inhibitors, HMG-Co A reductase inhibitors) impair 
hepatocellular cholesterol production by inhibiting the 
synthesis of mevalonate, a critical intermediary product 
in the cholesterol pathway. They are generally well toler-
ated, but can produce a variety of skeletal muscle-asso-
ciated, dose-dependent adverse reactions, ranging from 
muscle pain to frank rhabdomyolysis. Rhabdomyolysis is 
a serious adverse reaction of these drugs for both patients 
and the pharmaceutical industry, as evidenced by numer-
ous case reports and case series [1, 2] and the withdrawal 
from the market of cerivastatin in August 2001 [3].
The frequency of rhabdomyolysis is low, with a reported 
incidence of approximately 1 : 10 000 patient years [4] 
and a death rate of 0.15 per million prescriptions [3, 5]. 
The fact that the frequency of myotoxicity observed for 
cerivastatin was higher than for the other statins raised the 
question of whether there are differences in the myotoxic 
potential of the statins and whether such differences are 
related to their physicochemical properties. As shown in 
Table 1, differences in the physicochemical properties of 
statins can result in a variable kinetic behavior, including 
bioavailability, tissue distribution and metabolism, which 
may affect their toxic potential on skeletal muscle [6]. For 
example, inhibition of cytochrome P450 (CYP) isozymes 
can lead to increased bioavailability of lipophilic statins 
[7], thereby elevating the potential for myotoxicity. How-
ever, since myotoxicity has been reported with all statins 
on the market, the variability in their pharmacokinetic 
properties does not adequately explain the susceptibility 
to develop statin-induced myotoxicity.
Little is known regarding the mechanisms by which 
statins produce skeletal muscle injury. HMG-CoA reduc-
tase catalyses the formation of mevalonate from HMG-
CoA. Mevalonate is an important precursor not only of 
cholesterol but also of ubiquinone, dolichols and other 
isoprenoids [8]. All of these compounds are involved in 
various essential cell functions. A deficit in them may 
Research Article
Toxicity of statins on rat skeletal muscle mitochondria
P. Kaufmann, M. Török, A. Zahno, K. M. Waldhauser, K. Brecht and S. Krähenbühl*
Division of Clinical Pharmacology and Toxicology and Department of Research, University Hospital, 4031 Basel 
(Switzerland), Fax: +41 61 265 4560, e-mail: kraehenbuehl@uhbs.ch
Received 21 May 2006; received after revision 28 July 2006; accepted 25 August 2006
Online First 29 September 2006
* Corresponding author.
Cell. Mol. Life Sci. 63 (2006) 2415–2425
1420-682X/06/202415-11
DOI 10.1007/s00018-006-6235-z
© Birkhäuser Verlag, Basel, 2006
Cellular and Molecular Life Sciences
2416       P. Kaufmann Mitochondrial toxicity of statins
therefore adversely affect myocytes, rendering them vul-
nerable to myotoxic events [8, 9]. This hypothesis was 
strengthened by the observation that the myotoxicity of 
statins on myocytes in vitro could be decreased by the 
addition of mevalonate [10, 11]. Ubiquinone, whose bio-
synthesis is reduced in the presence of statins [8, 9], is 
utilized by mitochondria for the transport of electrons be-
tween enzyme complexes of the electron transport chain. 
Reduced levels of ubiquinone are present in specific 
forms of mitochondrial myopathies and are considered to 
result in impaired mitochondrial electron transport chain 
function and decreased adenosine triphosphate (ATP) 
synthesis [12, 13]. Regarding statins and mitochondria, 
light microscopic changes observed in muscle biopsies 
of patients with statin-associated myopathy were similar 
to the findings in patients with mitochondrial myopathies 
[14–17]. In a patient with rhabdomyolysis associated with 
simvastatin, MELAS syndrome manifested in the recov-
ery phase, suggesting that so far unnoticed mitochondrial 
diseases may represent risk factors for statin-associated 
myopathy [18]. Furthermore, in a recent study, Vladutiu 
et al. [19] described biochemical and/or genetic abnor-
malities of proteins or genes involved in skeletal muscle 
energy metabolism in more than 50% of patients with 
statin-associated myopathy. Recent in vitro investigations 
indicate that simvastatin interferes with mitochondrial 
calcium homeostasis and inhibits complex I of the elec-
tron transport chain [20].
On the basis of these reports, we hypothesized that statins 
could act as mitochondrial toxins and that the patients 
with an underlying mitochondrial disease could react 
preferentially with myopathy. Since the data about toxic-
ity of statins on mitochondria are still rare, we decided 
to investigate the effects of several statins on isolated rat 
skeletal muscle mitochondria and on L6 cells, a rat skel-
etal muscle cell line.
Materials and methods
Materials
Fluvastatin was a gift from Novartis Pharma (Basel, Swit-
zerland), simvastatin from Merck Sharp & Dohme (Ra-
haway, NJ, USA), cerivastatin from Bayer (Zürich, Swit-
zerland) and pravastatin from Bristol-Myers Squibb (San-
kyo, Japan). Atorvastatin was provided by Prof. J. Drewe 
(University Hospital Basel, Switzerland). Simvastatin 
lactone was converted to the corresponding acid as de-
scribed previously [21]. JC-1 was obtained from Alexis 
Biochemicals (Lausen, Switzerland) and [1-14C]palmitic 
acid from Amersham (Dübendorf, Switzerland). FAS li-
gand was prepared as described previously [22].
Fetal calf serum, all supplements and the culture me-
dium were from Gibco (Paisley, UK). The 96-well plates 
were purchased from Becton Dickinson (Franklin Lakes, 
NJ, USA) and the 8-chamber slides from Nalge Nunc 
(Rochester, NY, USA). The VybrantTM Apoptosis Assay 
Kit #2 was purchased from Molecular probes (Eugene, 
OR, USA). All other chemicals used were of best quality 
available and purchased from Sigma–Aldrich (Schnell-
dorf, Germany).
Animals
Male Sprague Dawley rats (Charles River, Les Onins, 
France) were used for all experiments. They were fed ad 
libitum, held on a 12-h dark and light cycle and weighed 
before their use. The study protocol had been accepted by 
the local Animal Ethics Committee.
Cells
L6 cell lines (rat skeletal muscle myoblasts) were ob-
tained from LGC Promochem (Wesel, Germany). The 
cell line was cultured in Dulbecco’s modified Eagle’s 
medium (Gibco 61965026; with 4 mmol/l GlutaMAX®, 
4.5 g/l glucose and sodium bicarbonate) supplemented 
with 10% heat-inactivated fetal calf serum, 1 mmol/l so-
dium pyruvate and 5 µl/ml penicillin-streptomycin. Cul-
ture conditions were 5% CO2 and 95% air atmosphere at 
37 °C.
Isolation of rat skeletal muscle mitochondria
At the time of killing, the rat weight averaged 389 g. The 
animals were first treated with carbon dioxide and then 
Table 1. Physiochemical properties, pharmakokinetic parameters and metabolism of the statins studied [5, 9].










Cerivastatin high < 40 60 99  21 CYP3A4/2C8 a 30/70
Fluvastatin high > 68  6 98  30 CYP2C9/3A4 6/90
Atorvastatin high > 70 12 80 381 CYP3A4 2/70
Simvastatin high ∼ 80  5 95 nk b CYP3A4 13/58
Pravastatin low   44–66 18 50  35 Conjugation 20/71
a CYP: cytochrome P450.
b nk: not known.
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killed by decapitation. The skeletal muscle of the hind 
legs (mean 19.0 g) was removed, freed from fat and con-
nective tissue, minced with scissors and homogenized 
according to Kerner and Hoppel [23]. From this homoge-
nate, skeletal muscle mitochondria were isolated accord-
ing to Palmer et al. [24].
The mitochondrial protein content was determined using 
the biuret method with bovine serum albumin (BSA) as 
a standard [25].
In vitro cytotoxicity assays
Cell injury was assessed by the determination of the 
activity of lactate dehydrogenase (LDH) in the super-
natant of statin-treated as compared with LDH activity 
in the supernatant of lysed cells (0.8% Triton X-100) 
[22]. LDH activity was analyzed as described by Vas-
sault [26]. Different concentrations of the compounds 
investigated and 100 mmol/l mevalonate (only to se-
lected incubations, see Results) were added to the cell 
cultures in a 96-well-plate for 24 h before the superna-
tants were harvested and analyzed. Control incubations 
were treated with the vehicle used to dissolve the sub-
stances investigated.
Mitochondrial membrane potential
Cells were detached from the cell culture flasks by add-
ing 10 mmol/l ethylenediamine-tetraacetic acid (EDTA) 
in phosphate-buffered saline pH 7.4 (PBS). After filtra-
tion, cells were adjusted to a density of 0.5 × 106 cells/
ml and incubated in complete medium in the dark. Be-
fore incubation, test substances, JC-1 (4 µg/ml) and 
100 µmol/l mevalonate (only to selected incubations, 
see Results) were added. Flow cytometry was performed 
after an incubation time of 10 min using a FACSCali-
bur flow cytometer (Becton Dickinson, San José, CA, 
USA). Changes in mitochondrial membrane potential 
(∆Ym) were monitored by measuring the JC-1 fluores-
cence using FL-1 and FL-2. FL denotes the measured 
fluorescence intensity in the respective channel (FL-1 = 
530 ± 15 nm, FL-2 = 585 ± 21 nm). Dinitrophenol (an 
uncoupler) and benzbromarone (depolarizes the ∆Ym 
[22]) served as controls.
Oxygen consumption
Oxygen consumption was monitored polarographically 
using a 1-mL chamber equipped with a Clark-type oxygen 
electrode (Yellow Springs Instruments, Yellow Springs, 
OH, USA) at 30 °C as described previously [27]. The fi-
nal concentration of l-glutamate was 20 mmol/l.
Oxygen consumption by intact mitochondria. The re-
spiratory control ratio (RCR) was calculated according to 
Estabrook [28]. The RCR represents the ratio between the 
rate of oxygen consumption in the presence of a substrate 
and ADP (state 3) and the rate after complete conversion 
of ADP to ATP (state 4).
The test compounds were added to the mitochondrial in-
cubations before the addition of the respective substrate. 
Control experiments were carried out in the presence of 
the solvent (1% DMSO) containing no inhibitor.
Oxygen consumption of L6 muscle cells. Cells (1 × 106) 
were treated with oligomycin (final concentration 5 µg/
ml) to inhibit F1F0-ATPase. After 2 min, test compounds 
were added to the incubation chamber and the oxygen 
consumption was determined. Control experiments were 
carried out with solvent (1% DMSO).
Activity of NADH-oxidase
The activity of NADH-oxidase was determined at 30 °C 
using freeze-thawed mitochondria as described originally 
by Blair et al. [29] with the modifications described ear-
lier [30].
In vitro mitochondrial β-oxidation and carinitine 
palmitoyltransferase activity
The β-oxidation of [1-14C]palmitic acid by skeletal mus-
cle mitochondria was assessed according to Sherratt et 
al. [31]. The incubation vials, which contained 500 µg 
mitochondrial protein in 900 µl incubation solution, were 
closed with a rubber stopper and incubated for 15 min 
at 30 °C. A scoop containing a filter paper soaked with 
90 µl 0.1 mol/l KOH was fixed at the rubber stopper and 
was used to trap the volatile 14CO2.
Carinitine palmitoyltransferase (CPT) activity was mea-
sured by the formation of palmitoyl-[3H]carnitine from 
palmitoyl-CoA and l-[3H]carnitine [32], a reaction mainly 
reflecting activity of CPT1. Palmitoylcarnitine was ex-
tracted with 1.4 ml water-saturated 1-butanol, which was 
washed with 600 µl butanol-saturated water [33] and 
quantified by liquid scintillation counting.
Activities of mitochondrial β-oxidation enzymes
All enzyme activities were determined using spectro-
photometric assays at 37 °C. Freeze-thawed mitochon-
dria were treated 1 : 1 with 5% cholic acid to disrupt 
the mitochondrial membranes. The solution was then 
diluted one hundred times with 50 mmol/l potassium 
phosphate buffer (pH 7.4). Acyl-CoA dehydrogenase 
was determined according to Hoppel et al. [27], using 
palmitoyl-CoA as a substrate. β-Hydroxy-acyl-CoA de-
hydrogenase was determined in the reverse direction ac-
cording to Brdiczka et al. [34] using acetoacetyl-CoA 
as substrate. β-Ketothiolase was determined using ace-
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toacetyl-CoA as a substrate according to Hoppel et al. 
[27].
Mitochondrial swelling
Mitochondrial swelling was monitored by measuring the 
decrease in light scattering at 540 nm using a Spectra-
MAX 250 plate reader (Paul Bucher Analytik und Bio-
technologie, Basel, Switzerland). The decrease in light 
scattering has been shown to correlate closely with the 
percentage of the mitochondrial population undergoing 
permeability transition [35]. Freshly isolated mitochon-
dria were suspended in isotonic swelling buffer (pH 7.3; 
150 mmol/l KCl, 20 mmol/l MOPS, 10 mmol/l Tris, 
2 mmol/l nitrilotriacetic acid and 2 µmol/l calcium iono-
phore A23187) and exposed to test compounds at room 
temperature. Swelling was calculated from the slope be-
tween 60 and 2000 s of exposure.
Cytochrome c immunocytochemistry
For immunocytochemistry, cells were grown in an eight-
chamber-slide for 24 h at 37 °C and then treated with the 
test compounds for 24 h. Cytochrome c was visualized by 
immunocytochemistry as described previously [22].
Cellular ATP content
Rat myoblasts (500 000 L6 cells/well) were transferred 
into a 12-well plate and treated for 24 h with test com-
pounds. Following treatment, cells were collected and the 
ATP content measured as described previously [22]. ATP 
concentrations were calculated using an ATP standard 
curve.
Determination of apoptosis
Both assays were performed using L6 muscle cells cul-
tured on poly-d-lysine coated (0.1 mg/ml, 30 min) cell 
culture dishes.
Hoechst 33342 nuclear staining. A confluent cell layer 
was treated for 24 h with test compounds, then incubated 
for 30 min at room temperature with Hoechst 33342 dye 
(50 µmol/l in PBS) and visualized by fluorescence mi-
croscopy (Olympus IX 50, Hamburg, Germany).
Annexin V and propidium iodide staining. An in situ 
apoptosis detection kit was used for Annexin V bind-
ing and propidium iodide (PI) staining (VybrantTM Apo-
ptosis Assay Kit #2). After a 24-h incubation with the 
test compounds, cells were stained with 25 µl Annexin 
V-Alexa Fluor® 488 and 2 µl PI (final concentration: 
1.5 µg/l). After 15 min of incubation at room tempera-
ture, samples were analyzed by flow cytometry, using 
a FACSCalibur flow cytometer (Becton Dickinson, San 
José, USA).
Statistical analysis
Data are presented as mean ± standard error of the mean 
(SEM). For statistical comparisons, data of groups were 
compared by analysis of variance (ANOVA). The level 
of significance was p ≤ 0.05. If ANOVA revealed signifi-
cant differences, comparisons between the control and the 
other incubations were performed by Dunnett’s post test 
procedure. A t-test (unpaired, two-tailed) was performed 
if only two groups were analyzed.
Results
In vitro cytotoxicity
Cytotoxicity was investigated by treating L6 cells with 
various concentrations of the different statins for 24 h. As 
shown in Figure 1, 100 µmol/l cerivastatin, fluvastatin, 
atorvastatin or simvastatin showed significant toxicity. In 
contrast, pravastatin did not cause any cell damage up 
to 1 mmol/l. Statin-associated cytotoxicity could not be 
prevented by the addition of 100 µmol/l mevalonate to 
the incubations (data not shown). Since lipophilic statins 
were toxic to muscle cells, further experiments were per-
formed to find out the mechanisms for cytotoxicity.
Mitochondrial membrane potential
Since statin-induced myopathy has been shown to be as-
sociated with mitochondrial dysfunction [14, 15], we first 
Figure 1. Cytotoxicity of the test compounds. Cerivastatin, fluvas-
tatin, atorvastatin and simvastatin caused a concentration-depen-
dent release of LDH from L6 cells into the cell culture media. In 
contrast, the cells were not destroyed by pravastatin up to 1 mmol/l. 
Data are expressed as the percentage of total LDH activity released 
into the cytoplasm and are presented as mean ± SEM of at least 
three individual experiments. *p < 0.05 vs. control, **p < 0.01 vs. 
control.
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focused on mitochondria. In a first step, we measured the 
∆Ym, since this potential is critical for myocyte survival 
[36] and its dissipation can be associated with induction 
of apoptosis [37]. As shown in Figure 2, at a concen-
tration of 100 µmol/l, 35% of the cells showed a dissi-
pated mitochondrial membrane potential in the presence 
of cerivastatin, and 51%, 20% or 26% in the presence 
of fluvastatin, atorvastatin or simvastatin, respectively. 
Figure 2. Assessment of the mitochondrial membrane potential. After labelling the cells with JC-1, mitochondrial depolarization could be 
visualized by a shift of the fluorescence emission from green to red. In the upper left quadrant, cells with polarized mitochondria are located 
(a, 1% DMSO), whereas cells with dissipated potential are found in the upper or lower right panels (b–d, fluvastatin 10 µmol/l, 100 µmol/l 
or 1000 µmol/l, respectively). In (e), the counts retrieved in the upper left quadrant are given as the percentage of total counts (defined as 
100%). Data are given as mean ± SEM of at least three individual experiments. *p < 0.05 vs. control, **p < 0.01 vs. control.
Figure 3. Uncoupling effect of statins. Uncoupling was determined by assessing the effect of statins on state 4 respiration in the presence 
of l-glutamate and oligomycin using L6 cells. In coupled mitochondria, blocking of the F1F0-ATPase by oligomycin results in a restricted 
electron transport and oxygen consumption similar to state 4. If a test compound works as an uncoupler, oxygen consumption increases, in 
spite of inhibited phosphorylation (a). Of the tested statins, only cerivatstatin worked as an uncoupler, whereas the other statins did not in-
crease oxygen consumption. Dinitrophenol and benzbromarone served as positive controls. *p < 0.05 vs. control, **p < 0.01 vs. control.
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The dissipation of the mitochondrial membrane poten-
tial could not be prevented by the addition of 100 µmol/l 
mevalonate to the incubations (data not shown).
Mitochondrial respiration
To further specify the mitochondrial defects, we assessed 
the toxicity of the statins on oxidative metabolism of iso-
lated rat skeletal muscle mitochondria. In the presence of 
l-glutamate as a substrate, cerivastatin, fluvastatin, ator-
vastatin and simvastatin induced a progressive depression 
of the RCR, which reflects the activity of the electron 
transport chain and the tightness of the coupling of oxida-
tive phosphorylation (see Table 2). The concentrations as-
sociated with a 50% decrease in the RCR were: 57 µmol/l 
for cerivastatin, 72 µmol/l for fluvastatin, 113 µmol/l for 
atorvastatin and 78 µmol/l for simvastatin. In contrast, 
pravastatin did not significantly affect the RCR up to 
400 µmol/l.
While the depression of the RCR by fluvastatin, atorvas-
tatin and simvastatin was mainly due to inhibition of state 
3 respiration (inhibition of the electron transport chain), 
for cerivastatin, the decrease was mostly due to accelera-
tion of state 4, suggesting uncoupling. We therefore de-
termined oxygen consumption by L6 cells in the presence 
of oligomycin, an inhibitor of F1F0ATPase (Fig. 3). Under 
these conditions, only cerivastatin showed an increase in 
state 4 respiration, demonstrating that cerivastatin uncou-
ples oxidative phosphorylation.
To exclude the possibility that the observed lack of toxic-
ity of pravastatin is due to its hydrophilicity, which could 
impair membrane permeation, the activity of the mito-
chondrial NADH oxidase (reflecting activities of complex 
I, III and IV) was measured using broken mitochondria. 
Also in the absence of membrane barriers, pravastatin 
up to 1 mmol/l did not impair the activity of the electron 
transport chain, whereas the lipophilic statins revealed 
significant inhibitory effects at ≥100 µmol/l (results not 
shown).
Fatty acid metabolism
For the assessment of β-oxidation by skeletal muscle mi-
tochondria, both the formation of acid soluble products 
and of CO2 were determined. [31] As shown in Figure 4a, 
cerivastatin (100 µmol/l), fluvastatin, atorvastatin and 
simvastatin (each 200 µmol/l) inhibited mitochondrial 
β-oxidation between 82% and 96%. For pravastatin, 
a significant inhibition of β-oxidation was found at 
(300 µmol/l). The corresponding IC50 were: 14 µmol/l 
for cerivastatin, 9.0 µmol/l for fluvastatin, 29 µmol/l for 
atorvastatin, 75 µmol/l for simvastatin and 300 µmol/l for 
pravastatin.
To localize the inhibitory effect of β-oxidation in more de-
tail, three enzymes of the β-oxidation were investigated. 
Acyl-CoA dehydrogenase was inhibited by 30–40% 
in the presence of 100 µmol/l cerivastatin, 200 µmol/l 
fluvastatin, atorvastatin or simvastatin, or 400 µmol/l 
pravastatin, and β-hydroxy-acyl-CoA dehydrogenase 
by 10–20% in the presence of 100 µmol/l cerivastatin, 
200 µmol/l fluvastatin, atorvastatin or simvastatin, or 
400 µmol/l pravastatin. In contrast, β-ketothiolase was 
not significantly inhibited by the statins used at the same 
concentrations as above.
Since there was some discrepancy between the inhibition 
of the β-oxidation pathway (using intact mitochondria) 
and individual enzymes (using disrupted mitochondria), 
we also determined the activity of CPT, which can be 
rate limiting for fatty acid oxidation [38]. As shown in 
Figure 4b, fluvastatin and cerivastatin inhibited CPT1 
activity, whereas the other statins revealed no signifi-
Table 2. Effects of cerivastatin, fluvastatin, atorvastatin, simvas-
tatin and pravastatin on oxidative metabolism of l-glutamate by 
isolated rat skeletal muscle mitochondria. See method section for 
experimental details. Mean ± SEM of at least three experiments 
using different mitochondrial preparations.
Control  
(no inhibitor)
State 3 State 4 RCR
233 ± 21 66 ± 14 3.7 ± 0.8
Cerivastatin (µmol/l)
 2 256 ± 23  69 ± 10 4.0 ± 0.6
 5 240 ± 31  69 ±  6 3.5 ± 0.4
 25 289 ± 35  88 ± 10 3.4 ± 0.5
 50 274 ± 35 137 ± 15* 2.0 ± 0.0
100 187 ± 19 187 ± 19** 1.0 ± 0.0**
Fluvastatin (µmol/l)
  5 241 ± 15  63 ±  7 3.9 ± 0.2
 25 224 ±  8  42 ± 21 3.5 ± 0.3
 50 266 ± 24  65 ±  6 2.3 ± 0.4
100 192 ± 41 126 ± 28* 1.7 ± 0.5*
200 116 ± 11** 116 ± 11* 1.0 ± 0.0**
Atorvastatin (µmol/l)
  5 171 ± 28 49 ±  3 3.4 ± 0.3
 25 173 ± 20 56 ±  1 3.1 ± 0.3
 50 161 ± 45 45 ±  9 3.5 ± 0.6
100 149 ±  6* 71 ± 11 2.2 ± 0.3*
200  45 ±  5** 45 ±  5 1.0 ± 0.0**
Simvastatin (µmol/l)
  5 200 ± 32 56 ±  6 3.0 ± 0.3
 25 213 ± 56 74 ± 16 2.8 ± 0.4
 50 157 ± 41 86 ± 18 1.9 ± 0.5*
100 123 ± 15* 80 ± 13 1.7 ± 0.5*
200  83 ±  9* 83 ±  9 1.0 ± 0.0**
Pravastatin (µmol/l)
 50 272 ± 25 92 ± 10 3.0 ± 0.4
100 338 ± 41 95 ± 28 2.9 ± 0.5
200 271 ± 36 82 ±  5 3.4 ± 0.5
300 247 ± 41 90 ± 12 2.7 ± 0.1
400 278 ± 73 88 ± 10 3.1 ± 0.5
*p < 0.05 vs. control; **p < 0.01 vs. control.
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cant inhibitory effect up to 200 µmol/l (atorvastatin) or 
1 mmol/l (simvastatin, pravastatin).
Mitochondrial swelling and release of cytochrome c
As already demonstrated, statins did cause a loss of the 
mitochondrial membrane potential. We therefore hypoth-
esized that statins might induce mitochondrial permeabil-
ity transition, which can result in mitochondrial swelling 
and cytochrome c release [39]. As shown in Figure 5, 
cerivastatin, fluvastatin, atorvastatin and simvastatin in-
duced mitochondrial swelling in a concentration-depen-
dent manner, whereas pravastatin did not cause an open-
ing of the mitochondrial permeability transition pore.
As a consequence of the mitochondrial permeability 
transition pore opening, cytochrome c release from the 
mitochondrial intermembrane space into the cytoplasm 
can occur, which can trigger the mitochondrial pathway 
of apoptosis [40]. To assess this possibility, cytochrome 
c release into cytoplasm was determined. As shown in 
Figure 6, only pravastatin did not induce a release of cyto-
chrome c from the mitochondria, whereas in the presence 
of the lipophilic statins, cytochrome c was spilled into 
the cytoplasm.
Mechanisms of cell death
Cytoplasmic cytochrome c can activate caspases and 
induce apoptosis [41]. DNA fragmentation occurring 
Figure 4. Effect of statins on β-oxidation and CPT1 activity. Fatty acid oxidation (a) was determined using isolated rat skeletal muscle 
mitochondria and was impaired by all lipophilic statins in a concentration-dependent manner (IC50 9.9–76 µmol/l). In contrast, pravastatin 
inhibited fatty acid oxidation with an IC50 of 300 µmol/l. Data are given relative to control values (100% activity corresponds to 3.90 nmol/
mg mitochondrial protein/min). In (b), the effect of statins on CPT1 activity using isolated mitochondria was determined. Cerivastatin and 
fluvastatin are inhibitors of CPT1, whereas the other three statins investigated do not affect CPT1 activity. Data are given relative to control 
values (100% activity corresponds to 6.45 nmol/mg mitochondrial protein/min). Data are given as mean ± SEM of at least three individual 
experiments. *p < 0.05 vs. control, **p < 0.01 vs. control.
Figure 5. Induction of mitochondrial permeability transition. Mi-
tochondrial permeability transition was monitored as a decrease 
in absorbance at 540 nm. Upon pore opening, osmotically driven 
influx of water into the mitochondrial matrix leads to mitochon-
drial swelling, causing a change in the light scattering properties of 
mitochondria. Ca2+ was used as positive control. Among the tested 
statins, only pravastatin did not induce mitochondrial permeability 
transition, whereas all lipophilic statins caused a concentration-
dependent increase in mitochondrial size. *p < 0.05 vs. control; 
**p < 0.01 vs. control.
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during apoptosis can be visualized by fluorescence mi-
croscopy using dyes intercalating with DNA. As shown 
in Figure 7, untreated cells showed an apoptosis rate of 
1.1%. At a concentration of 100 µmol/l, the proportion 
of apoptotic cells was 13% for cerivastatin, 11% for flu-
vastatin, 6% for atorvastatin, 6% for simvastatin and 1% 
for pravastatin.
Another hallmark of the early stages of apoptosis is the 
translocation of phosphatidylserine from the inner to the 
outer leaflet of the plasma membrane, which can be de-
tected by Annexin V. Cells were co-stained with PI as a 
marker of cell membrane permeability, which increases 
during the later stages of apoptosis and also in necro-
sis. Since PI only enters cells with already disintegrated 
membranes, early apoptotic cells can be distinguished 
from late apoptotic and necrotic cells. Similar to the 
stainings with Hoechst 33342, flow cytometric analysis 
of the cells revealed a progressive increase of the An-
nexin V signal (early apoptotic cells) with increasing 
concentrations of lipophilic statins. At 100 µmol/l of 
these compounds, between 9% and 17% of cells under-
went early apoptotic changes. In contrast, only 3% of 
cells treated with 100 µmol/l pravastatin were Annexin V 
positive (data not shown). Fas ligand, used as a positive 
control for apoptosis induction, induced early apoptosis 
in 12% of cells. Similarly, only the lipophilic statins, but 
not pravastatin, caused late apoptosis/necrosis (data not 
shown).
Since ATP is essential for executing apoptosis [39, 42], 
the cellular ATP content was assessed. The ATP content 
in control incubations was 1.26 ± 0.08 µmol/106 myo-
cytes and remained stable in presence of 100 µmol/l flu-
vastatin, atorvastatin, simvastatin or pravastatin. In the 
presence of 100 µmol/l cerivastatin, it dropped to 0.16 
Figure 6. Mitochondrial release of cytochrome c. L6 cells were 
incubated with test compounds (each 100 µmol/l) for 24 h and 
cytochrome c was detected by immunocytochemistry. In the pres-
ence of 1% DMSO (a, negative control) or pravastatin (g), no leak-
age into the cytoplasm occurred (the nuclei are clearly visible and 
cytochrome c is distributed in the cytoplasm with a granular pat-
tern). After treatment with benzbromarone (positive control, b), 
cerivastatin (c), fluvastatin (d ), atorvastatin (e) or simvastatin ( f ), 
cytochrome c was released from the mitochondrial intermembrane 
space into the cytoplasm (most nuclei covered by cytochrome c and 
the cytoplasm stained diffusely).
Figure 7. Detection of apoptosis by staining with Hoechst 33342. L6 cells were treated with test compounds at a concentration of 100 µmol/
l for 24 h and subsequently stained with Hoechst 33342. The cell nuclei were visualized using fluorescence microscopy. (a) Control, (b) 
atorvastatin, (c) pravastatin. Apoptotic cells were characterized by DNA condensation (b, arrow a) and/or DNA fragmentation (b, arrow 
b). (d ) Summary of the percentage of cells undergoing apoptosis. Pravastatin was the only statin not inducing apoptosis. *p < 0.05 vs. 
control; **p < 0.01 vs. control.
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±0.09 µmol/106 myocytes, suggesting that also necrosis 
occurred.
Discussion
Our investigations demonstrate that lipophilic statins 
are mitochondrial toxins affecting the electron transport 
chain, coupling of oxidative phosphorylation and/or mito-
chondrial β-oxidation. These alterations in mitochondrial 
function are associated with dissipation of the electric po-
tential across the inner mitochondrial membrane. The mi-
tochondrial membrane potential is mainly maintained by 
a proton gradient generated by the proton pump activity 
of complexes I, III and IV of the electron transport chain. 
Any perturbation of these enzyme complexes and/or un-
coupling of oxidative phosphorylation can be expected to 
dissipate the mitochondrial membrane potential, which 
can therefore be regarded as a marker of mitochondrial 
function and integrity. A decrease in the mitochondrial 
membrane potential can lead to mitochondrial membrane 
permeabilization, which is considered to be a point-of-
no-return for initiating apoptotic cell death [41, 43]. Mi-
tochondrial membrane permeabilization can culminate 
in rupture and therefore loss of barrier function of the 
outer mitochondrial membrane, with consequent release 
of apoptosis-inducing proteins (e.g. cytochrome c) from 
the mitochondrial intermembrane space.
Our study shows that lipophilic statins act along this en-
tire sequence: they inhibit the function of the electron 
transport chain, impair mitochondrial β-oxidation (lim-
ited availability of NADH for the function of complex I 
of the electron transport chain), uncouple oxidative phos-
phorylation (cerivastatin), decrease the mitochondrial 
membrane potential, and induce mitochondrial swelling 
and apoptosis. The induction of apoptosis by statins may 
not only be initiated by the mitochondrial pathway, how-
ever. Due to inhibition of the conversion of HMG-CoA to 
mevalonate, not only the synthesis of cholesterol, but also 
of intermediates between HMG-Co A and cholesterol 
and products of these intermediates (e.g. ubiquinone and 
dolichols) is reduced [8]. As a consequence, cells may 
become poor in prenylated (farnesylated or geranylated) 
small GTP proteins, such as Rho, Ras or Rac, which pro-
mote cell maintenance and cell survival [3, 44, 45]. Since 
mevalonate could not prevent statin-associated mito-
chondrial damage and cytotoxicity, mitochondrial toxic-
ity and not impaired prenylation of GTP proteins appears 
to initiate apoptosis of L6 cells. Patients treated with 
statins may have an increased basal rate of apoptotic cell 
death, which is compensated by cell proliferation under 
normal conditions. In the case an additional insult, e.g. a 
large increase in the statin plasma and tissue concentra-
tions due to a drug-drug interaction and/or an underlying 
metabolic disease [19], there may be a massive increase 
in apoptotic cell death, possibly leading to organ damage 
such as rhabdomyolysis.
Our findings support the results of Kubato et al. [46], 
who showed that lipophilic statins can cause apoptosis of 
hepatocytes. Also in these experiments, pravastatin nei-
ther reduced cell viability nor induced apoptosis. Since a 
reduction in cholesterol synthesis could also be shown for 
pravastatin, the hydrophilic pravastatin also had to have 
entered the hepatocytes to execute its pharmacological 
action. At least in hepatocytes, inhibition of cholesterol 
synthesis is therefore not sufficient to induce apoptosis.
Although all lipophilic statins tested induced apoptosis 
of skeletal muscle cells, their effects on mitochondrial 
function differed among each other. For instance, only 
cerivastatin uncoupled oxidative phosphorylation (see 
Fig. 3). The uncoupling capacity of cerivastatin is obvi-
ously not related to its pharmacological action, but may 
offer an explanation for its higher myotoxicity compared 
with the other statins [2, 5, 6, 47]. When mitochondrial 
uncoupling occurs, protons are transported into the mi-
tochondrial matrix by bypassing the F1F0-ATPase. As a 
consequence, the mitochondrial membrane potential is 
dissipated and mitochondrial ATP synthesis is decreased, 
possibly leading to cellular ATP depletion and cytotoxic-
ity [39]. Furthermore, uncouplers may be transported into 
and accumulate within the mitochondrial matrix, which 
could enhance their toxicity. The higher myotoxicity of 
cerivastatin compared with other statins may therefore be 
explained by its higher bioavailability (see Table 1) and 
by its capability to uncouple oxidative phosphorylation 
of skeletal muscle mitochondria.
Having investigated muscle toxicity of statins in vitro, the 
question arises, to what extent our findings are relevant 
for the in vivo situation. For atorvastatin, pravastatin and 
atorvastatin, typical plasma concentrations after oral 
doses of 20–40 mg are in the range of 0.1 µmol/l [5, 48], 
which is considerably lower than the toxic concentrations 
determined in our investigations. Since data of statin 
concentrations in skeletal muscle of humans are so far 
lacking, possible tissue concentrations reached have to be 
estimated. The volume of distribution of lipophilic statins 
(Table 1) is high for atorvastatin, low for the statins with 
high protein binding (cerivastatin and fluvastatin) and un-
known for simvastatin (intermediate protein binding). At 
least for atorvastatin (and possibly also for simvastatin), 
accumulation in peripheral tissues can be assumed, pos-
sibly also in skeletal muscle. Furthermore, most cases 
of rhabdomyolysis with statins have been described in 
patients having a drug-drug interaction [1], leading to 
plasma (and possibly also tissue) concentrations which 
are higher (in some cases tenfold or even more [49]) than 
normal concentrations. Since it is known that even in the 
presence of a drug-drug interaction, only a minority of the 
patients develop rhabdomyolysis [50], patients affected 
by muscular problems may have an underlying (possibly 
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mitochondrial) disease, rendering them more sensitive to 
lower statin concentrations [19]. Taken together, our find-
ings may be relevant for the in vivo situation in sensitive 
humans, although the statin concentrations associated 
with mitochondrial toxicity found in our study appear to 
be high.
Similar to the study of Kubota et al. [46], our investi-
gations do not offer an explanation for in vivo skeletal 
muscle toxicity of pravastatin, which appears to have an 
equal frequency as for atorvastatin and simvastatin [4]. In 
our assays, pravastatin revealed only a slight inhibition of 
mitochondrial β-oxidation at high concentrations, but did 
not induce apoptosis or necrosis of L6 cells. A lack of ac-
cess to cell organelles can be excluded by our own studies 
(NADH oxidase) and also by the studies of Kubota et al. 
[46]. The possibilities remain that a metabolite of pravas-
tatin is the culprit or that L6 cells are not a suitable cell 
system to show toxicity for this particular statin.
In conclusion, the lipophilic statins impair several func-
tions of skeletal muscle mitochondria, whereas as the hy-
drophilic pravastatin does not reveal a relevant mitochon-
drial toxicity in vitro. Although the toxic concentrations 
of the statins on isolated mitochondria and L6 cells are 
considerably higher than their plasma concentrations in 
humans, mitochondrial toxicity may trigger rhabdomy-
olysis in sensitive patients. Since the hydrophilic pravas-
tatin is also associated with rhabdomyolysis, additional 
mechanisms may exist.
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